Brumm Joshua T insider trades
Brumm Joshua T has filed 25 Form 4s with the SEC that we hold, for Dyne Therapeutics, Inc. (DYN) (CEO & President, Director) and Crescent Biopharma, INC. (CBIO) (Chief Executive Officer, Director). Across all of them we count 0 purchases worth $0 and 34 sales worth $27.6M reported on Form 4. In the last 12 months: 0 purchases ($0) and 3 sales ($920.8K). The largest single trade was a sale of 202,238 shares of Dyne Therapeutics, Inc. worth $5.1M, dated 2024-03-08. Of 2 sales filed since we began reading the 10b5-1 checkbox, 2 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-09-22 and the latest 2026-09-18.
Dyne Therapeutics, Inc. (DYN)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2021-09-20 | S, sale reported on Form 4 | 3,425 | $53.5K | 2021-09-22 | SEC |
| 2021-09-21 | S, sale reported on Form 4 | 4,584 | $73.8K | 2021-09-22 | SEC |
| 2022-03-11 | S, sale reported on Form 4 | 3,384 | $29.5K | 2022-03-14 | SEC |
| 2022-10-07 | S, sale reported on Form 4 | 14,200 | $189.9K | 2022-10-11 | SEC |
| 2022-10-10 | S, sale reported on Form 4 | 195,800 | $2.4M | 2022-10-11 | SEC |
| 2022-12-12 | S, sale reported on Form 4 | 3,322 | $36.1K | 2022-12-13 | SEC |
| 2023-03-14 | S, sale reported on Form 4 | 7,318 | $97.5K | 2023-03-15 | SEC |
| 2023-06-08 | S, sale reported on Form 4 | 46,811 | $615.6K | 2023-06-12 | SEC |
| 2023-06-08 | S, sale reported on Form 4 | 14,189 | $191.1K | 2023-06-12 | SEC |
| 2023-06-09 | S, sale reported on Form 4 | 76,582 | $1.0M | 2023-06-12 | SEC |
| 2023-06-12 | S, sale reported on Form 4 | 187,748 | $2.4M | 2023-06-12 | SEC |
| 2023-09-12 | S, sale reported on Form 4 | 7,672 | $79.9K | 2023-09-13 | SEC |
| 2023-09-18 | S, sale reported on Form 4 | 12,032 | $113.2K | 2023-09-20 | SEC |
| 2023-12-11 | S, sale reported on Form 4 | 7,585 | $81.3K | 2023-12-12 | SEC |
| 2024-01-03 | S, sale reported on Form 4 | 15,382 | $282.1K | 2024-01-04 | SEC |
| 2024-01-03 | S, sale reported on Form 4 | 19,775 | $376.3K | 2024-01-04 | SEC |
| 2024-01-03 | S, sale reported on Form 4 | 16,026 | $328.5K | 2024-01-04 | SEC |
| 2024-01-04 | S, sale reported on Form 4 | 38,301 | $729.6K | 2024-01-04 | SEC |
| 2024-01-04 | S, sale reported on Form 4 | 180,235 | $3.3M | 2024-01-04 | SEC |
| 2024-02-29 | S, sale reported on Form 4 | 5,520 | $151.8K | 2024-03-01 | SEC |
| 2024-03-01 | S, sale reported on Form 4 | 74,090 | $2.2M | 2024-03-01 | SEC |
| 2024-03-01 | S, sale reported on Form 4 | 18,976 | $536.1K | 2024-03-01 | SEC |
| 2024-03-01 | S, sale reported on Form 4 | 1,414 | $42.0K | 2024-03-01 | SEC |
| 2024-03-07 | S, sale reported on Form 4 | 9,086 | $234.9K | 2024-03-11 | SEC |
| 2024-03-08 | S, sale reported on Form 4 | 202,238 | $5.1M | 2024-03-12 | SEC |
| 2024-03-08 | S, sale reported on Form 4 | 160,670 | $4.3M | 2024-03-12 | SEC |
| 2024-03-08 | S, sale reported on Form 4 | 435 | $11.9K | 2024-03-12 | SEC |
| 2024-03-11 | S, sale reported on Form 4 | 8,618 | $223.5K | 2024-03-12 | SEC |
| 2024-03-11 | S, sale reported on Form 4 | 40,072 | $1.0M | 2024-03-12 | SEC |
| 2024-03-11 | S, sale reported on Form 4 | 9,928 | $259.1K | 2024-03-12 | SEC |
| 2024-03-11 | S, sale reported on Form 4 | 7,769 | $202.9K | 2024-03-12 | SEC |
Crescent Biopharma, INC. (CBIO)
Counted from the Form 4 filings this reporting owner (SEC CIK 1528826) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
